Mounjaro®
Starting from £179.99/mo
Start journey Learn moreIf you are on tirzepatide and have an operation coming up, you need to let your surgical and anaesthetic team know — and you will almost certainly need to pause the medicine before your procedure. Tirzepatide slows how quickly the stomach empties food into the gut, and that slower gastric emptying raises the risk of regurgitation and aspiration of stomach contents during anaesthesia, even when you have followed standard fasting instructions. This is the central safety concern, and it applies whether your surgery is planned or urgent. These are prescription-only medicines, and any decision about when to stop or restart must be made with your prescribing clinician and surgical team — not guessed at or based on general internet advice.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Tirzepatide works partly by activating GIP and GLP-1 receptors in the gut, which slows the rate at which the stomach passes food into the small intestine. In everyday use, that slower transit is part of why appetite falls and meals feel more filling. But in an operating theatre it creates a specific problem: even after several hours of fasting, the stomach may still hold more fluid or partially digested food than your anaesthetist would expect. If you are sedated or given a general anaesthetic, the usual reflexes that protect your airway are suppressed, and any stomach contents that rise up can enter the lungs, a complication called pulmonary aspiration that can be serious. If you want to understand why tirzepatide cannot be taken before surgery, the physiology behind that aspiration risk is explained in detail on that page.
This is not a theoretical risk raised only by cautious pharmacists. NHS England's guidance on weight-management injections explicitly states that patients should tell their full healthcare team, including the anaesthetist, that they are taking tirzepatide before any surgical procedure. The anaesthetic team uses that information to adjust fasting times, choose techniques, and put additional airway precautions in place if they judge them necessary. Keeping the medicine a secret to avoid complications or awkward questions is the one approach that genuinely raises risk.
A question our prescribers hear most weeks is whether a short day procedure or local anaesthetic counts. The honest answer is: tell your team regardless, and let them decide. Some procedures carry far less risk than a full general anaesthetic; others that sound minor still require sedation. Your surgical team is better placed than any online source to make that call for your specific case.
Current clinical practice in the UK is that tirzepatide is usually paused before planned surgery, but the exact timing is not fixed in a single universal protocol, different surgical centres and professional societies have issued guidance, and your anaesthetic team's instructions take precedence over any general figure you read online. For a detailed look at the timing question and what the clinical guidance actually says, our page on when to stop Mounjaro before surgery sets out what is known and what remains under active clinical discussion.
What is clear is that the longer tirzepatide's gastric-emptying effect has to resolve before a general anaesthetic, the lower the aspiration risk. Because tirzepatide has a long half-life (it remains pharmacologically active for many days after an injection) a pause of one week is not the same as a complete washout. The prescribing decision involves your dose, your injection schedule, the type of anaesthesia planned, and what your surgery is for. For practical guidance on stopping Mounjaro before surgery, including how to time your pause around your injection schedule, that page covers the steps patients and prescribers typically work through together. If your operation is urgent or emergency surgery, you may not have the option to wait, and your surgical team will take precautions accordingly.
If you are a nume patient and have surgery scheduled, contact us through our support team as soon as a date is confirmed. We will coordinate with your prescriber so that your pause is documented and your restart plan is ready when you need it.
Restarting tirzepatide after surgery is equally important to plan. How and when to restart after your procedure depends on factors including how quickly you can eat and drink normally, whether you had abdominal surgery, how your recovery is going, and what dose you were on before the pause. It is not simply a case of picking up the next injection on the original schedule.
GI function needs to have recovered sufficiently, because the medicine's appetite-reducing and gastric-slowing effects could compound nausea or slow recovery in the early post-operative period. Your surgical team and your prescriber should agree a restart point. Some patients find that after a period off treatment (particularly if they have been eating very little during recovery) their prescriber recommends reintroducing at a lower dose to manage tolerability before returning to the previous level. That is a clinical conversation, not a fixed rule.
If you would like to understand the broader picture of what the relationship between tirzepatide and surgery involves across different procedure types, that page goes into greater depth. For anything specific to your situation, speak to our prescribers through the consultation, and make sure your surgical team has the full picture on your medicines. You can also review the NHS patient information on tirzepatide for the medicine's general guidance on interactions and special precautions.
The short answer: everyone involved in your care. Your GP if they are not already aware you are on tirzepatide. Your surgical consultant. The anaesthetist, who may be a different person and may not automatically see your full medicine list until the pre-operative assessment. Your pharmacist if you pick up other medicines in the lead-up to surgery. And if you are a patient at a private clinic like nume, your prescriber there too.
Pre-operative assessments are the ideal moment to raise this. Bring your pen or packaging so the dose and strength are clear. If you have had a recent dose increase, say so, the question of how long since your last injection matters as much as which medicine you take. MHRA Drug Safety Updates relating to GLP-1 medicines, including the January 2026 update on pancreatitis, are publicly available if your clinician wants to review the current safety landscape alongside your situation. And if you have further questions about how tirzepatide fits into your weight-management plan more broadly, our Mounjaro treatment overview explains how the medicine works and what starting treatment involves.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.